Advertisement

Standardized Treatment Strategy for Depressive Disorder

  • Zuowei WangEmail author
  • Xiancang Ma
  • Chunlan Xiao
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1180)

Abstract

The treatment strategies of depressive disorder include pharmacological treatment, psychotherapy, and physical therapy (electroconvulsive therapy [ECT], transcranial magnetic stimulation [TMS], etc.). The updated CANMAT guidelines recommended the most second-generation antidepressants as first-line treatments for patients with a major depressive disorder (MDD) of moderate or greater severity. Before antidepressant treatment, comprehensive assessment and safety monitoring are necessary. The application of measurement-based care in the diagnosis and treatment of depression would better ensure that enough dosage and response of antidepressant is achieved at each key point, and the final outcome of disease is improved. It is recommended that antidepressant is used with monotherapy in patients with depression. Antidepressants of different types and different mechanisms could be combined to improve the efficacy for patients with treatment-resistant depression (TRD). To prevent the relapse and recurrence of disease, the long-term treatment comprised of acute treatment, consolidation treatment, and maintenance treatment must be considered for all patients.

Keywords

Depressive disorder Treatment Pharmacology Standardized 

References

  1. Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C (2012) Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 10:CD006533Google Scholar
  2. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391(10128):1357–1366CrossRefGoogle Scholar
  3. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T, Strobelberger M, Lloyd S, Reichenpfader U, Lohr KN (2011) Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 155(11):772–785CrossRefGoogle Scholar
  4. Hieronymus F, Emilsson JF, Nilsson S, Eriksson E (2016) Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 21:523–530CrossRefGoogle Scholar
  5. Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P et al (2016) Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological Treatments. Can J Psychiatry/La Rev Can Psychiatr 1–21Google Scholar
  6. Kuga A, Tsuji T, Hayashi S, Matsubara M, Fujikoshi S, Tokuoka H, Yoshikawa A, Escobar R, Tanaka K, Azekawa T (2017) An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis. Neuropsychiatr Dis Treat 4(13):2105–2114CrossRefGoogle Scholar
  7. Lam RW, McIntosh D, Wang J, Enns MW, Kolivakis T, Michalak EE, Sareen J, Song WY, Kennedy SH, MacQueen GM, Milev RV, Parikh SV, Ravindran AV (2016) CANMAT depression work group. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. Disease burden and principles of care. Can J Psychiatry 61(9):510–523CrossRefGoogle Scholar
  8. Li LJ, Ma X (2015) Practice guideline for prevention and treatment of depressive disorder (in Chinese). Chin Soc Psychiatry, BeijingGoogle Scholar
  9. Nam B, Bae S, Kim SM, Hong JS, Han DH (2017) Comparing the effects of bupropion and escitalopram on excessive internet game play in patients with major depressive disorder. Clin Psychopharmacol Neurosci 15(4):361–368CrossRefGoogle Scholar
  10. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA (2011) Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev (12):CD006528.  https://doi.org/10.1002/14651858.cd006528

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Hongkou District Mental Health CenterShanghaiChina
  2. 2.The First Affiliated Hospital of Xi’an Jiaotong UniversityXi’anChina

Personalised recommendations